arrow
A

Amiri-Kordestani, Laleh

us food & drug administration (fda)
H指数:0
被引数:118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

FDA批准摘要: Enfortumab Vedotin联合Pembrolizumab治疗局部晚期或转移性尿路上皮癌

2024-09-040
PRE
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
2023-05-2232
OA
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

FDA批准摘要: Lu 177 Vipivotide四氧唑烷用于转移性去势抵抗性前列腺癌患者

2022-12-0592
OA
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
2022-06-2163
OA
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
2021-12-1629
OA
US FDA Drug Approvals for Gynecological Malignancies: A Decade in Review
2021-10-2810
OA
US FDA Drug Approvals for Breast Cancer: A Decade in Review
2021-10-2844
OA
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
2021-04-280
OA
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
2021-03-2288
OA
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
2021-03-0141
OAAI
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
2020-11-132
PREAI
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
2020-11-09105
OAAI